Aelis Farma Announces Completion of Patient Randomization for Phase 2b Study with AEF0117 for the Treatment of Cannabis Addiction – Medical Marijuana Program Connection

BORDEAUX, France–(BUSINESS WIRE)–Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain disorders, today announces to have reached a key milestone by successfully completing the recruitment of 333 patients suffering from cannabis addiction in its Phase 2b clinical study with AEF0117. AEF0117 is the first of a new class of proprietary drugs developed by Aelis Farma, the Signaling Spec

Source link

• SEO Powered Content & PR Distribution. Get Amplified Today.
• PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
• PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
• PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
• PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
• Source: https://mmpconnect.com/aelis-farma-announces-completion-of-patient-randomization-for-phase-2b-study-with-aef0117-for-the-treatment-of-cannabis-addiction/?utm_source=rss&utm_medium=rss&utm_campaign=aelis-farma-announces-completion-of-patient-randomization-for-phase-2b-study-with-aef0117-for-the-treatment-of-cannabis-addiction